{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:07:20Z","timestamp":1789560440837,"version":"build-2803163510"},"reference-count":0,"publisher":"Archives of Endocrinology and Metabolism","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["A&amp;EM"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Neuroendocrine tumors (NETs) are rare neoplasms that present significant challenges during pregnancy, particularly in the\ncontext of metastatic disease or carcinoid syndrome requiring systemic therapy. Data on the safety of somatostatin analogs\nduring pregnancy remain limited and are primarily derived from studies involving patients with acromegaly. We report the maternal\nand fetal outcomes in a pregnant patient diagnosed with a metastatic NET of the ileocecal valve, complicated by carcinoid\nsyndrome. The patient had previously undergone treatment with 177Lu-DOTATATE, debulking surgery, and lanreotide therapy.\nLanreotide administration was continued throughout the pregnancy under multidisciplinary supervision. Maternal monitoring\nrevealed no complications, and postpartum evaluations confirmed disease stability. The newborn developed transient neonatal\nhyperbilirubinemia requiring phototherapy but demonstrated normal development at the 18-month follow-up. This case\nhighlights important clinical considerations regarding the continuation of somatostatin analog therapy, biochemical monitoring,\nperi-delivery planning for a carcinoid crisis, and pregnancy after peptide receptor radionuclide therapy in patients with functioning\nmetastatic NETs. It provides supportive observational evidence that the continuation of lanreotide during pregnancy\nmay be feasible in carefully selected patients under close multidisciplinary supervision, although conclusions regarding safety\nremain limited by the rarity of available data.<\/jats:p>","DOI":"10.20945\/2359-4292-2026-0102","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:35:21Z","timestamp":1789558521000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy"],"prefix":"10.20945","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0035-8538","authenticated-orcid":false,"given":"Beatriz Tavares","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-4557","authenticated-orcid":false,"given":"Ariana","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8073-9734","authenticated-orcid":false,"given":"Maria Teresa","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4425-628X","authenticated-orcid":false,"given":"Sara","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5229-3130","authenticated-orcid":false,"given":"Susana","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1218-3743","authenticated-orcid":false,"given":"Joana","family":"Vilaverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1756-6142","authenticated-orcid":false,"given":"Marta Sales","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6164-0502","authenticated-orcid":false,"given":"Clara","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8896-305X","authenticated-orcid":false,"given":"Ana Paula","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9883-3809","authenticated-orcid":false,"given":"Jorge","family":"Dores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","published-online":{"date-parts":[[2026]]},"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"link":[{"URL":"https:\/\/www.aem-sbem.com\/article\/pregnancy-in-a-patient-with-metastatic-functioning-midgut-neuroendocrine-tumor-receiving-lanreotide-after-peptide-receptor-radionuclide-therapy\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:35:22Z","timestamp":1789558522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/pregnancy-in-a-patient-with-metastatic-functioning-midgut-neuroendocrine-tumor-receiving-lanreotide-after-peptide-receptor-radionuclide-therapy\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":0,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026]]},"published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.20945\/2359-4292-2026-0102","relation":{},"ISSN":["2359-3997"],"issn-type":[{"value":"2359-3997","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}